China's CARsgen Therapeutics raised HKD3.1bn ($400.3m) gross in an initial public offering on the Hong Kong Stock Exchange (HKEX) on 17 June, helping the chimeric antigen receptor T-cell (CAR-T) the
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Kyongbo Inks Antibiotics CMO Pacts With